Tagliabue A, Boraschi D, Villa L, Keren D F, Lowell G H, Rappuoli R, Nencioni L
J Immunol. 1984 Aug;133(2):988-92.
Antibody-dependent cellular cytotoxicity (ADCC) against murine enteropathogenic bacteria such as Salmonella typhimurium and Salmonella tel aviv or Shigella X16 was assessed by using IgG, IgA, and secretory IgA (sIgA) in a 2-hr in vitro assay where peripheral and intestinal lymphocytes were used as effector cells. It was found that IgG could arm splenocytes (SpL) better than IgA. However, IgG did not arm lymphocytes from Peyer's patches (PPL) or from mesenteric lymph nodes (MnL), whereas IgA of plasmacytoma origin against S. tel aviv and purified intestinal sIgA against Shigella X16 induced specific antibacterial ADCC with both SpL and PPL. When sIgA were tested with intestinal lymphocytes from the epithelium and the lamina propria, i.e., cells from the gut mucosa which first interact with enteric bacteria, it was found that both these lymphoid populations were able to express sIgA-dependent ADCC against Shigella X16. In parallel tests, cells from thymus and popliteal lymph nodes failed to express ADCC. Blocking studies with purified IgG and IgA of goat, rabbit, and mouse origin demonstrated that the Fc-alpha and Fc-gamma receptors were specifically involved in IgA- or IgG-dependent antibacterial ADCC. At least two effector populations, a macrophage and a Thy-1.2- lymphocyte, were observed to exert IgA-ADCC at the splenic level, whereas only lymphoid cells expressed this activity at the GALT level. Together, these results describe a new activity of IgA against enteropathogenic bacteria.
通过使用IgG、IgA和分泌型IgA(sIgA),在一项为期2小时的体外试验中评估了针对鼠源肠道病原菌(如鼠伤寒沙门氏菌、特拉维夫沙门氏菌或志贺氏菌X16)的抗体依赖性细胞毒性(ADCC),该试验中使用外周血和肠道淋巴细胞作为效应细胞。结果发现,IgG比IgA更能武装脾细胞(SpL)。然而,IgG不能武装派伊尔结淋巴细胞(PPL)或肠系膜淋巴结淋巴细胞(MnL),而源自浆细胞瘤的针对特拉维夫沙门氏菌的IgA和针对志贺氏菌X16的纯化肠道sIgA可诱导SpL和PPL产生特异性抗菌ADCC。当用来自上皮和固有层的肠道淋巴细胞(即首先与肠道细菌相互作用的肠道黏膜细胞)测试sIgA时,发现这两种淋巴细胞群体均能够表达针对志贺氏菌X16的sIgA依赖性ADCC。在平行试验中,来自胸腺和腘窝淋巴结的细胞未能表达ADCC。用山羊、兔子和小鼠来源的纯化IgG和IgA进行的阻断研究表明,Fc-α和Fc-γ受体特异性参与IgA或IgG依赖性抗菌ADCC。在脾脏水平观察到至少两种效应细胞群体,即巨噬细胞和Thy-1.2淋巴细胞发挥IgA-ADCC作用,而在肠道相关淋巴组织(GALT)水平只有淋巴细胞表达这种活性。总之,这些结果描述了IgA针对肠道病原菌的一种新活性。